(Q44512469)

English

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

8

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Srdan Verstovsek

5

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Jorge Eduardo Cortes

2

object named as

Jorge Cortes

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Guillermo Garcia-Manero

4

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

7

object named as

Maher Albitar

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Apostolia Maria Tsimberidou

1

object named as

Apostolia Tsimberidou

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

9

object named as

Elihu Estey

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Francis J Giles

10

object named as

Francis J Giles

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

6

object named as

Stephan Faderl

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Deborah Thomas

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Leukemia Research

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

893-897

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg).

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2803%2900022-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0145-2126(03)00022-5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44512469&oldid=2070300753"